MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has ...

Immuron Limited has announced an exclusive distribution agreement to launch ProIBS® in Australia and New Zealand, targeting symptoms of irritable bowel syndrome (IBS) through retail pharmacies. This ...

Immuron Limited ( (AU:IMC)) has provided an announcement. Immuron reported unaudited global first-half sales of AUD$4.2 million, up 5% year-on-year, driven primarily by strong performance of its ...

Immuron Limited has announced strong progress in several key projects, including expected sales exceeding A$7 million this financial year, a significant increase from last year’s A$4.9 million. The ...

US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical products Travelan ® Clinical Study: Topline results from the Travelan ® clinical ...

ProIBS ® is a certified medical device for the treatment of IBS symptoms such as abdominal pain, bloating and unsettled bowel movements (diarrhoea and/or constipation). ProIBS ® contains AVH200 ®, ...